title: Treating IgA nephropathy: quid novi?
abstract: IgA nephropathy is a common autoimmune renal disease resulting in kidney failure for patients with significant proteinuria. The therapeutic options are limited including non-specific treatment to reduce proteinuria accomplished by renin-angiotensin blockade. Strategies to control intrarenal inflammation include the administration of fish oil and for severe disease the use of immunosuppressive agents such as cyclophosphamide, glucocorticosteroids, and mycophenolate mofetil. In light of the limited option, there is an unmet need for novel therapeutic intervention in patients with progressive disease. Herein, we review the evidence for existing treatment choices and explore new immunopharmacologic agents being investigated for IgA nephropathy.
authors.affiliation: The Rogosin Institute, 505 East 70th St., Box 102, New York, NY 10021, USA and Division of Nephrology and Hypertension, Weill Cornell Medical College, 525 East 68th St., New York, NY 10065, USA.
authors.forename: Choli
authors.initials: C
authors.lastname: Hartono
authors.forename: Thangamani
authors.initials: T
authors.lastname: Muthukumar
mesh_terms: D000936:Antigen-Antibody Complex / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D005395:Fish Oils / Q000627:therapeutic use; D005922:Glomerulonephritis, IGA / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use
chemical_list: D000936:Antigen-Antibody Complex; D001323:Autoantibodies; D001324:Autoantigens; D005395:Fish Oils; D007166:Immunosuppressive Agents